CRISPR, patents, and the public health

Research output: Contribution to journalArticlepeer-review


Patent issues surrounding CRISPR, the revolutionary genetic editing technology, may have important implications for the public health. Patents maintain high prices for novel therapies, limiting patient access. Relatedly, insurance coverage for expensive therapies is waning. Patents also misallocate research and development resources to profitable disease indications rather than those that necessarily impinge on the public health. And it is unclear how CRISPR therapies will figure into the current regulatory framework for biosimilars. Policy makers and physicians should consider these issues now, before CRISPR therapies become widely adopted—and entrenched—in the marketplace.

Original languageEnglish (US)
Pages (from-to)667-672
Number of pages6
JournalYale Journal of Biology and Medicine
Issue number4
StatePublished - Dec 2017
Externally publishedYes


  • Biosimilars
  • Drug prices
  • Gene therapy
  • Insurance
  • Neglected diseases
  • Patents
  • Public health

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'CRISPR, patents, and the public health'. Together they form a unique fingerprint.

Cite this